Mode
Text Size
Log in / Sign up

Giant cell arteritis

Part of Vasculitis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Giant cell arteritis

10 trials tracked for Giant cell arteritis: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 131 citations.

10Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 5 Phase 1 1 Other / NA 2
  1. Phase 3 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Completed · 131 cited
  2. Phase 4 Tocilizumab Plus a Short Prednisone Taper for GCA Completed · 33 cited
  3. Phase 2 Baricitinib in Relapsing Giant Cell Arteritis Completed
  4. Phase 2 KPL-301 for Subjects With Giant Cell Arteritis Completed
  5. Phase 2 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed
  6. Phase 2 Tocilizumab for Patients With Giant Cell Arteritis Completed
Show 4 more trials
  1. Phase 2 A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Completed
  2. Phase 1 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). Completed
  3. N/A Validation of a Diagnostic Algorithm of Giant Cell Arteritis Completed
  4. N/A Assessment of Giant Cell Arteritis Medical Practices in France Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.